When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and ...

Antares Therapeutics has launched with $177 million in series A financing and a staff already at full speed, according to CEO Adam Friedman. The company is a spin-off of Scorpion Therapeutics, which ...

The rest of Scorpion’s assets were to be spun out into a new company. That startup, Boston-based Antares Therapeutics, launched Tuesday. Scorpion was founded in 2020 by serial biotech ...

Additional support came from Abingworth, Invus, Tenmile, Vida Ventures, Vinyanshu Ventures and Willett Advisors.

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

Antares will use that cash to advance a group of small molecule drugs Scorpion had been working on, as well as programs the company had been advancing through a 2022 partnership with AstraZeneca.